Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences

Patients and medical professionals may call 1-800-533-UPMC (8762) for more information.
 

 

 

 

 

 

UPMC Media Relations

​UPMC Beginning Gene Therapy Study to Grow New Blood Vessels in the Heart

PITTSBURGH, April 3, 1998 — Cardiologists at the University of Pittsburgh Medical Center (UPMC) are beginning a clinical trial of a gene therapy treatment to stimulate the growth of new blood vessels to increase the supply of blood to the heart. These newly formed vessels will provide an alternate route for blood to bypass clogged and blocked arteries in the heart. The process is called angiogenic gene therapy and selectively delivers human fibroblast growth factor(FGF) genes into the hearts of patients.

"This represents a fundamentally new and different way of treating coronary artery disease," said Joon Sup Lee, M.D., assistant professor of medicine in the division of cardiology at the UPMC and principal investigator in the study. "The treatment may eventually help angina patients who have exhausted other means of heart revascularization such as angioplasty and bypass surgery.

"The patients who would benefit most from the treatment are those who are not candidates for conventional angioplasty or bypass surgery. They may have small, completely blocked or narrowed vessels which make them unsuitable for conventional therapy but good for angiogenesis."

The UPMC is one of 10 centers participating in the phase I/II trial. A total of 60 patients nationwide will be treated, about 10 at UPMC. Patients will range in age from 50 to 75 years.

In the treatment, a catheter is inserted into the femoral artery and then threaded into the coronary arteries where the FGF gene, by way of a human adenovirus-5 vector, is delivered.

The vector used for this gene therapy, the human adenovirus, which is responsible for a short-lived cold, is modified so that it will not produce an infection. The genetically engineered virus is carried into the heart muscle where it produces specific proteins that initiate growth of new collateral blood vessels. The process is designed to enhance the heart’s natural healing process by providing an additional stimulus to promote angiogenesis.

"Based on pre-clinical studies, we would hope to see the development of collateral blood vessels within two to four weeks," Dr. Lee said. "We will use a treadmill exercise test, a stress echocardiogram and other standard evaluation methods after four weeks and then again after eight weeks to determine any functional improvements in the patients."

Coronary artery disease, primarily caused by atherosclerosis, affects nearly 14.5 million Americans. It is the leading cause of death in industrialized nations and claims the lives of nearly 500,000 people in the U.S. annually. Each year, approximately 400,000 coronary angioplasties and 500,000 coronary artery bypass surgeries are performed to provide relief from advanced atherosclerosis.

FGF is manufactured by Collateral Therapeutics, a San Diego-based biotechnology company focused on the discovery, development and commercialization of novel and innovative gene therapy products for the treatment of cardiovascular disease.

Please visit University of Pittsburgh Medical Center's Cardiovascular Institute website for more information on cardiology services and programs.

 

©  UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences
Supplemental content provided by A.D.A.M. Health Solutions. All rights reserved.

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on UPMC.com is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, UPMC.com is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

For UPMC Mercy Patients: As a Catholic hospital, UPMC Mercy abides by the Ethical and Religious Directives for Catholic Health Care Services, as determined by the United States Conference of Catholic Bishops. As such, UPMC Mercy neither endorses nor provides medical practices and/or procedures that contradict the moral teachings of the Roman Catholic Church.

© UPMC
Pittsburgh, PA, USA UPMC.com